4.7 Article

Role of endogenous opioid peptides in the infarct size-limiting effect of adaptation to chronic continuous hypoxia

Journal

LIFE SCIENCES
Volume 93, Issue 9-11, Pages 373-379

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.lfs.2013.07.018

Keywords

Chronic hypoxia; Myocardial infarction; Cardioprotection; Opioid peptides; Opioid receptors

Funding

  1. Russian Foundation of Basic Research, Ministry of Education and Sciences of Russian Federation [11.519.11.2028, 8827]
  2. Czech Science Foundation [303/12/1162]

Ask authors/readers for more resources

Aims: The objective of this study was to examine the involvement of endogenous opioid peptides and opioid receptor (OR) subtypes in the cardioprotective effect of adaptation to chronic hypoxia in rats. Main methods: Rats were exposed to continuous normobaric hypoxia (CNH; 12% oxygen) for 3 weeks. Myocardial ischemia was induced by 20-min coronary artery occlusion followed by 3-h reperfusion in anesthetized open-chest animals. Various OR antagonists were administered to rats prior to ischemia. The size of myocardial infarction and the incidence of ischemic ventricular arrhythmias were assessed. Myocardial and plasma concentrations of opioid peptides (met-enkephalin, beta-endorphin, and endomorphins) were determined. Key findings: Adaptation to CNH significantly increased myocardial and plasma concentrations of opioids, potentiated their further elevation by ischemia/reperfusion, and reduced myocardial infarct size, but it did not affect the incidence of ischemic arrhythmias. The infarct size-limiting effect of CNH was abolished by OR antagonists naltrexone (non-selective), naloxone methiodide (non-selective peripherally acting), TIPP[Psi] (delta-OR), naltriben (delta(2)-OR), or CTAP (mu-OR), while BNTX (delta(1)-OR) and nor-binaltorphimine (kappa-OR) had no effect. Significance: The results suggest that the infarct size-limiting effect afforded by adaptation to CNH is mediated by activation of peripheral delta(2)- and mu-ORs by elevated levels of endogenous opioid peptides. (C) 2013 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available